None listed
Conditions
Interventions
Drug : This study is a study to prove the non-inferiority of DAPT use for 3 months compared to DAPT use for 12 months in patients who underwent coronary intervention using Everolimus-Eluting Stent. Th
Sponsors
Seoul National University Bundang Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Adults 19 years of age or older ? Patients with coronary artery disease requiring coronary intervention ? Patients who underwent percutaneous coronary intervention with centum stent, everolimus-eluting stent
Exclusion criteria
Exclusion criteria: ? Subjects with known history of severe hypersensitivity reactions to aspirin, clopidogrel, everolimus, contrast agent ? If there is clinically active bleeding at the time of study enrollment (active bleeding) ? Subjects who underwent stenting in the unprotected left main coronary artery ? Subjects whose life expectancy is less than 1 year for reasons other than cardiovascular disease ? Pregnant or lactating women ? If it is difficult to maintain dual antiplatelet therapy for anticoagulant treatment due to atrial fibrillation, etc. ? Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiac and cerebrovascular events: all cause death, target-vessel myocardial infarction, target lesion revascularization, and stent thrombosis, stroke | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause and cardiac death, MI (target vessel or any), Any repeat revascularization, Clinically-indicated target lesion revascularization (TLR), Clinically-indicated target vessel revascularization (TVR), Patient-oriented composite endpoint, Device-oriented composite endpoint, Stent thrombosis (ARC definition), Stroke, TIMI major and minor bleeding, BARC bleeding (3/5 and 2/3/5) | — |
Countries
Korea, Republic of
Contacts
Public ContactKi-Mi Park
Seoul National University Bundang Hospital
Outcome results
None listed